BridgeBio Pharma Inc’s experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its market shares by 65%. Acoramidis functions to prevent heart failure by addressing anomalous protein deposits in the heart. It is expected to compete with Alnylam Pharmaceuticals’ Patisiran and Pfizer’s Vyndamax, both used for similar conditions. Acoramidis was found to be 1.8 times better than a placebo for preventing death, hospitalization and improving walking distance. Compared to the placebo, the drug improved survival by 81% and reduced heart disease-related hospitalization by 50%.
However, despite promising results, the company clarified that a direct comparison between acoramidis and Vyndamax’s effectiveness was not the trial’s objective. BridgeBio plans to submit data to the FDA by the end of 2023 for a marketing application.
To read more, click here.
[Source: Reuters, July 17th, 2023]